Participate in polls relating to real-time continuous glucose monitoring and see how your answers relate to your colleagues.

According to the webcast

with Richard Bergenstal, MD; Steven Edelman, MD and Boris Kovatchev, PhD:
A therapeutic Continuous Glucose Monitor (CGM) may be covered by Medicare when which of the following criteria is/are met:
The beneficiary has diabetes mellitus
The beneficiary has been using a home blood glucose monitor (BGM) and performing frequent (four or more times a day) BGM testing
The beneficiary is insulin-treated with multiple daily injections of insulin or a continuous subcutaneous insulin infusion pump
The beneficiary's insulin treatment regimen requires frequent adjustment by the beneficiary on the basis of therapeutic CGM testing results
All of the above

©2021 CogniMed Inc. All rights reserved.